Pfizer Inc. (PFE) delivered a surprise profit in the fourth quarter despite a double-digit contr✨action in revenue. Pfizer shares were up 1.8% in early trading Tuesday following the release.

While 澳洲幸运5官方开奖结果体彩网:analysts expected wider quarterly losses, the company posted a surprise adjusted income of $593 million or 10 cents per diluted share. That's roughly 91% lower than the figures from the same period in the prior year.

Revenue contracted about 41% to $14.2 billion as demand for its COVID-related products—Comirnaty and Paxlovid—weakened further even. Taking those two products out of the mix, the company's revenues grew 8% or $934 million.

In 2024, the company hopes to capitalize on its non-COVID revenue streams further and reap some of the benefits from its 澳洲幸运5官方开奖结果体彩网:acquisition of Seagen. The company said 🐲it expects 2024 revenue in the range of $58.5 billion to $61.5 billion, including $3.1 bi🅠llion from Seagen and $8 billion from Comirnaty and Paxlovid.

Adjusted diluted EPS guidance of $2.05 to $2.25 is a shade lower than previously anticipated as the company expects expense𒁏s related to Seagen to shave off about 40 cents per share.